Summary:
cells at the time of leukapheresis by enumeration of stem/progenitor cells expressing the cell surface antigen CD34. 2 The CD34 antigen is expressed on rare mononuclear cells in the peripheral blood and on 2-4% of mononuclear cells in the marrow. These putative stem cells have multilineage progenitor cell activity in vitro 3, 4 and are capable of reconstituting long-term hematopoiesis in nonhuman primates 5 and in human subjects following myeloablative chemotherapy. 6 These cells can be mobilized into the peripheral blood in significantly higher numbers using recombinant cytokines alone 7 or in combination with chemotherapy. 8, 9 The adequacy of leukapheresed autologous peripheral stem cell harvests is typically described by the yield of CD34 + cells collected. Numerous groups have established that rapid hematopoietic reconstitution following myeloablative chemotherapy depends upon the number of CD34 + cells collected. 2, [10] [11] [12] A minimum threshold of 2-2.5 ϫ 10 6 CD34 + cells/kg in the PBSC collection has been associated with prompt engraftment 1, 2 and CD34 + cell doses greater than 10 ϫ 10 6 /kg 11 and greater than 15 ϫ 10 6 /kg 12 may further accelerate hematopoietic recovery. Processing and cryopreservation undoubtedly render some cells nonviable and diminish the absolute number of CD34 + cells available for reinfusion. The impact of reduced cell viability on time to hematopoietic reconstitution in autologous peripheral stem cell transplantation has not been systematically studied.
A single platform flow cytometric method is available for rapid determination of absolute CD34 + cells, based on guidelines developed for the International Society of Hematotherapy and Graft Engineering (ISHAGE). [13] [14] [15] The single step method was adapted from a dual platform strategy that required a hematology analyzer for determination of total white cell concentration. 13 The dual platform method has been well validated in several clinical studies that included rates of hematopoietic reconstitution. 12, 16, 17 institution and displayed excellent correlation with the dual platform method. 13 Single platform CD34 + cell enumeration by flow cytometry allows real-time assessments of graft adequacy at the time of collection to ensure minimum thresholds are reached. As well, this method can be applied after thawing cryopreserved stem cells to assess the effect of processing. Viability of mononuclear cells is determined using the exclusion dye 7-amino actinomycin D and can be easily combined with absolute CD34
+ cell counting to enumerate viable CD34 + cells. 13, 20 The accuracy of CD34 + cell enumeration and viability testing was extremely high in a recent study of thawed cord blood samples, 21 providing important validation of the single platform methodology.
The aim of this study was to determine the cumulative effects of cryopreservation, thawing and washing of peripheral blood stem cell collections on CD34
+ cell viability and to evaluate the association between the number of thawed CD34 + cells and rates of hematopoietic engraftment following autologous peripheral blood stem cell transplantation.
Patients and methods

Patients and transplantation protocol
Thirty-seven consecutive patients who underwent autologous stem cell transplantation between February 1999 and January 2001 at the London Health Sciences Centre were identified. One patient was excluded from analysis due to lack of availability of CD34 + cell viability testing. Following informed consent, patients underwent autologous peripheral blood stem cell transplantation for multiple myeloma (16 patients), relapsed Hodgkin's lymphoma (14 patients), relapsed non-Hodgkin's lymphoma (three patients), and as consolidation therapy for germ cell tumors (three patients). To mobilize CD34 + cells, patients received one of three regimens: (1) recombinant human granulocyte colony-stimulating factor (G-CSF) 10 g/kg/day for 5 days (30 patients); (2) cyclophosphamide 2.5 g/m 2 followed by G-CSF for 11 days (one patient); or (3) cyclophosphamide, G-CSF and recombinant human stem cell factor (SCF) 20 g/kg/day for 11 days (five patients). Leukapheresis was performed using a COBE Spectra machine (Sorin Biomedica Canada, Ontario, Canada) after the mobilization treatment to obtain a target yield of Ͼ2.0 ϫ 10 6 CD34 + cells/kg. Disease-specific myeloablative chemotherapy was administered 3 days prior to receiving the stem cells. . Patients did not receive recombinant cytokines during the period of hematopoietic reconstitution. Blood products were transfused using the following general thresholds or at the discretion of the treating physician. Two units of packed red cells were transfused if the hemoglobin was less than 80 g/l and 5 units of random donor platelets if platelets were less than 10 ϫ 10 9 /l or less than 15 ϫ 10 9 /l and the patient was febrile.
Cryopreservation and processing
Peripheral stem cell products were either processed immediately after collection or stored overnight at 4ºC following the addition of 50 ml of autologous plasma. All PBSC packs were processed by centrifugation at 4200 r.p.m. for 9 min and excess plasma was removed while maintaining the white blood cell count below 500 ϫ 10 9 /l. Concentrated stem cell packs were then diluted with an equal volume of a mixture composed of 2 parts M199 tissue culture media (Canadian Life Technologies, Toronto, Canada), 2 parts patient plasma, and 1 part dimethylsulfoxide (DMSO, final concentration 10%). Ratecontrolled freezing was performed using a liquid nitrogen rate-controlled freezer (Planar Biomed, Mississauga, Canada) beginning at a rate of Ϫ1ºC/min to Ϫ5ºC, quick freezing from Ϫ5ºC to Ϫ10ºC, followed by rate-controlled freezing at a rate of Ϫ1ºC/min to Ϫ60ºC and then Ϫ5ºC/min to Ϫ100ºC. The PBSC product was then stored in liquid nitrogen at Ϫ100ºC until the day of reinfusion. The concentration of protein in the final product was not determined routinely. Prior to reinfusion, PBSC packs were thawed in a waterbath at 40ºC followed by the addition of acid citrate dextrose (ACD; MedSep Corporation, Ottawa, Canada; the volume added was 20% of stored PBSC volume) and 500 units deoxyribonuclease (DNAse, Sigma, Oakville, Canada). The thawed product was then added to a unit of compatible allogeneic donor red blood cells and washed on a COBE 2991 machine to reduce the risks associated with infusing unwashed cells. Washing was performed similarly to previously reported methodology 22 by diluting PBSC packs with saline to a final volume of 600 ml followed by centrifugation at 3000 r.p.m. for 10 min. Supernatant waste was removed at 100 ml/min using the COBE 2991 machine and the remaining product was agitated for 3 min. Saline was added again to yield a final volume of 600 ml and the washing process was repeated until the supernatant was clear or until 90 min had elapsed.
Absolute CD34 counts
Absolute numbers of CD34
+ cells were enumerated immediately following harvest and an aliquot of the washed donor red cells containing the CD34 + cells for reinfusion was sent for flow cytometric analysis. All samples were analyzed using the three-color single platform variant of the ISHAGE guidelines and included the addition of the viability dye 7-amino actinomycin D (7-AAD) as previously described. 13, 14 This method allows the measurement of viable CD34
+ cells directly by a flow cytometer without the need for a hematology analyzer, and a direct assessment of total leukocyte and CD34
+ cell viability in a single tube. The details of this method have been extensively described elsewhere 13, 14 and only the basics are described here. StemKIT (Beckman-Coulter/Immunotech, Hialeah, FL, USA) which utilizes CD45FITC/CD34PE and Stem-COUNT fluorescent immunospheres was used for determining absolute CD34 + counts. One hundred l of diluted blood was added to 20 l of CD45FITC (clone J33)/CD34PE (clone 581) and 20 l 7-AAD (final concentration 1 g/ml). All samples were prepared in duplicate.
Tubes were then incubated for 15 min at 4ºC and the red blood cells lysed with ammonium chloride for 10 min. Samples were stored on ice until analysis (within 10 min). There were no wash steps used in the procedure. Immediately before analysis 100 l of StemCOUNT fluorospheres were added and tubes analyzed on a Beckman-Coulter XL-MCL flow cytometer. A total of 75 000 CD45 events were collected per tube (see Figure 1) . 
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Engraftment data
Peripheral blood cell counts were determined daily. Patient charts were reviewed to verify the time to platelet recovery, defined as the first of 3 consecutive days with a platelet count greater than 20 ϫ 10 9 /l and without platelet transfusion in the 48 h preceding the first of these 3 consecutive days. Time to neutrophil recovery was defined as the first of 3 days with a neutrophil count greater than 0.5 ϫ 10 9 /l. The transfusion record was reviewed for each patient and information regarding fevers, use of antibiotics, and number of days in hospital was recorded.
Statistical analysis
Statistical analysis was performed using SSPS statistical software. Mann-Whitney rank sum test was used to assess differences in the number of CD34
+ cells between patients who engrafted before or after the median. Fisher's exact test was performed to compare differences in the proportion of patients meeting specific thresholds of CD34 + cell numbers in patient groups engrafting before or after the median. The Kruskal-Wallis one-way analysis of variance on ranks was followed by pairwise multiple comparisons according to Dunn's method to detect differences in rates of engraftment between the three groups of patients stratified on the basis of CD34 + cell numbers.
Results
Cohort patient characteristics
The 36 patients studied had a median age of 41 (range 16-68). Diagnosis, total days admitted to hospital, use of antibiotics, and transfusion requirements are presented in Table 1 .
Cohort stem cell characteristics
The median number of CD34 + cells harvested during leukapheresis was 3.6 ϫ 10 6 /kg (range 1.3-182 ϫ 10 6 ) with 99% mononuclear cell viability (range 99-100%). Following cryopreservation, stem cell products contained a median of 2.0 ϫ 10 6 viable CD34 + cells/kg (range 0.7-110 ϫ 10 6 ) with 76% overall mononuclear cell viability (range 46-91%). At the time of stem cell harvesting, the number of patients with fewer than 2 ϫ 10 6 , 2-5 ϫ 10 6 , or greater than 5 ϫ 10 6 CD34 + cells/kg was three, 20, and 13, respectively, while the number of patients in each stratification after thawing of cryopreserved stem cells was 17, 13 and six, respectively. Specifically, six of 13 patients (46%) who initially had greater than 5 ϫ 10 6 CD34 + cells/kg harvested had only 2-5 ϫ 10 6 /kg following cryopreservation and one patient had fewer than 2 ϫ 10 6 /kg remaining. In addition, 13 of 20 patients (65%) with 2-5 ϫ 10 6 CD34 + cells/kg collected had fewer than 2 ϫ 10 6 /kg prior to reinfusion. Although 33 of 36 patients (92%) exceeded the minimum threshold of 2 ϫ 10 6 CD34 + cells/kg at the time of collection, only 19 patients (53%) achieved this threshold at the time of reinfusion.
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Time to engraftment
The median time to platelet and neutrophil engraftment was 14 days (range 9-42) and 13 days (range 9-22), respectively. When viable CD34 + cells enumerated after thawing were Ͻ2 ϫ 10 6 /kg (group I), 2-5 ϫ 10 6 /kg (group II), or Ͼ5 ϫ 10 6 /kg (group III), the median time to platelet engraftment was 17 (range 12-42), 12 (range 11-16) and 10 days (range 9-14), respectively (P Ͻ 0.05 for pairwise comparison between groups I and II and between groups I and III; see Methods). The median time to neutrophil engraftment for groups I, II and III was 13 (range 10-22), 14 (range 10-19) and 12 days (range 9-13), respectively (P values not significant in pairwise comparison between groups).
Patients with recovery of platelets after the median of 14 days were compared with those engrafting platelets on or before the median (see Table 2 ). For the 14 patients engrafting beyond the median, the number of viable CD34
+ cells measured after thawing was 1.7 ϫ ) for the 22 patients engrafting on or before the median (P ϭ 0.003). Although 86% of patients who engrafted beyond 14 days exceeded the minimum threshold of 2.0 ϫ 10 6 CD34 + cells/kg at the time of harvesting, only 14% had this critical number after thawing whereas 68% of those who engrafted earlier still had Ͼ2.0 ϫ 10 6 cells/kg after thawing (P ϭ 0.002). Of those engrafting on or before 14 days, 27% had Ͼ5 ϫ 10 6 CD34
+ cells/kg after thawing compared with 0% of patients who engrafted later (P ϭ 0.06). A similar comparison was made concerning neutrophil engraftment (see Table 3 ). The 15 patients engrafting after the median of 13 days were compared with the 21 patients engrafting on or before the median. The number of viable CD34 + cells after thawing was 1.8 ϫ 10 6 /kg (range 0.7-3.2 ϫ 10 6 ) for patients engrafting after the median compared with 2.5 ϫ 10 6 CD34 + cells/kg (range 0.8-110 ϫ 10 6 ) for patients engrafting on or before 13 days (P ϭ 0.12).
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+ cell viability and engraftment DS Allan et al 971 Table 3 Comparing early and delayed neutrophil engraftment Of patients engrafting after the median, only 33% met the threshold of 2.0 ϫ 10 6 CD34 + cells/kg measured after thawing and none had Ͼ5.0 ϫ 10 6 /kg. Of those engrafting on or before the median, 57% had Ͼ2.0 ϫ 10 6 CD34 + cells/kg (P ϭ 0.19) and 29% had Ͼ5.0 ϫ 10 6 /kg after thawing (P ϭ 0.03).
Discussion
Single platform flow cytometry is a simple one-step method that allows determination of viable CD34
+ cell numbers prior to reinfusion of stem cell products. This method allows accurate assessment of viability loss due to stem cell processing. Previous studies have assessed the effect of various storage conditions on loss of CD34 + viability 23, 24 although, to our knowledge, no studies have reported a correlation with clinical engraftment data. A quantitative relationship between the number of viable thawed CD34
+ cells and time to platelet engraftment but not neutrophil recovery is suggested by our data. Interestingly, loss of CD34 + cell viability causes some patients to fall below the threshold of 2.0 ϫ 10 6 /kg and these patients, on average, experienced slower hematopoietic reconstitution. The effect of reduced CD34 + cell viability seems more important for platelet engraftment than for neutrophils although the small numbers in our study limit direct com- Identifying patients at risk of delays in hematopoietic reconstitution may alter some aspects of patient care following PBSC transplantation. Cytokines could prove beneficial in this population. Faster recovery of neutrophils was reported for subgroups of patients that received cytokines following stem cell infusion in two retrospective studies. 11, 16 Slower platelet recovery, however, is often more affected by reduced CD34 + cell numbers and some studies have suggested post-infusion cytokines may further delay platelet engraftment. 16, 25 Prophylactic antibiotics might be appropriate if increased rates of infection were detected in this group and more aggressive nutritional interventions such as total parenteral nutrition may be considered earlier in these patients. CD34 + cell numbers probably combine with other factors in determining time to hematopoietic reconstitution. Different myeloablative conditioning regimens have variable stem cell toxicity and previous chemotherapy regimens can affect the efficacy of stem cell harvesting and regrowth of the autograft. Infection and antibiotics may also suppress engraftment in some patients. Larger studies looking at more homogenous patient populations may better define the contribution of viable CD34
+ cell dose and time to engraftment.
Assessing CD34 + cell viability at different stages of processing allows for accurate quality control. Alterations in the cryopreservation or collection technique can be measured in their effect on CD34 + cell viability. Also, products that are cryopreserved for lengthy periods, such as cord blood samples, can be assessed for quality using the single platform flow cytometric methodology . 26 In summary, cryopreservation and processing of autologous stem cell collections significantly reduces the number of viable CD34 + cells available for reinfusion. The number of viable CD34 + cells reinfused is associated with time to hematopoietic engraftment in autologous transplantation, particularly recovery of platelet production. Loss of CD34 + cell viability causes many patients to fall below 2 ϫ 10 6
CD34
+ cell viability and engraftment DS Allan et al
972
Bone Marrow Transplantation CD34 + cells/kg. Measuring CD34 + cell viability may be useful in quality control assessments of stem cell processing and further studies may reveal ways of identifying patients at risk of delayed engraftment.
